Use of dietary supplements by breast cancer patients undergoing conventional cancer treatment
- PMID: 21206516
- PMCID: PMC3003607
- DOI: 10.2147/PPA.S13639
Use of dietary supplements by breast cancer patients undergoing conventional cancer treatment
Abstract
Background: Many breast cancer patients use some form of dietary supplement (DS) to complement their conventional cancer treatment, in the hope that they might lessen the side effects of treatment, improve quality of life, give a greater sense of control, and reduce stress. This pilot study assessed the level of DS usage by breast cancer patients undergoing conventional cancer treatment, and their concerns about the use of DS.
Method: A cross-sectional descriptive survey in three breast cancer centers in Hong Kong using face-to-face interviewing was performed.
Results: Of 82 female Chinese breast cancer patients who completed the survey, 99% reported that they had been using DS since their cancer was diagnosed. The most frequently used DS were Chinese herbal medicines, and patients spent about US$258 on DS every month. The reason given for using DS was to enhance their recovery from cancer, but at the same time the patients had safety concerns. However, most patients did not feel able to discuss these concerns with health professionals.
Conclusion: The majority of the patients had some safety concerns, and said that they would welcome detailed and reliable information on DS. The lack of reliable information on the potential risks and benefits of using such supplements as an adjuvant to conventional treatment and the reluctance of patients to discuss their use of DS with health professionals is a major area of concern that warrants further attention.
Keywords: breast cancer; concern; dietary supplement; expense; prevalence.
Similar articles
-
Dietary supplement usage by patients with cancer undergoing chemotherapy: does prognosis or cancer symptoms predict usage?J Support Oncol. 2007 Apr;5(4):195-8. J Support Oncol. 2007. PMID: 17500507
-
Herbal Products and Dietary Supplements: A Cross-Sectional Survey of Use, Attitudes, and Knowledge Among the Lebanese Population.J Community Health. 2016 Jun;41(3):566-73. doi: 10.1007/s10900-015-0131-0. J Community Health. 2016. PMID: 26659604
-
Use of Dietary Supplements at a Comprehensive Cancer Center.J Altern Complement Med. 2018 Sep/Oct;24(9-10):981-987. doi: 10.1089/acm.2018.0183. J Altern Complement Med. 2018. PMID: 30247972
-
An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series.Food Chem Toxicol. 2017 Sep;107(Pt A):449-471. doi: 10.1016/j.fct.2016.11.001. Epub 2016 Nov 3. Food Chem Toxicol. 2017. PMID: 27818322 Review.
-
The state of dietary supplement adverse event reporting in the United States.Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):962-70. doi: 10.1002/pds.1627. Pharmacoepidemiol Drug Saf. 2008. PMID: 18613260 Review.
Cited by
-
Is Danggui Safe to be Taken by Breast Cancer Patients?-A Skepticism Finally Answered by Comprehensive Preclinical Evidence.Front Pharmacol. 2019 Jun 25;10:706. doi: 10.3389/fphar.2019.00706. eCollection 2019. Front Pharmacol. 2019. PMID: 31293425 Free PMC article.
-
Potential factors that influence usage of complementary and alternative medicine worldwide: a systematic review.BMC Complement Med Ther. 2020 Nov 23;20(1):363. doi: 10.1186/s12906-020-03157-2. BMC Complement Med Ther. 2020. PMID: 33228697 Free PMC article.
-
An innovative anti-cancer Chinese herbal formula exhibited multi-targeted efficacies in metastatic breast cancer mouse model.Chin Med. 2018 Dec 22;13:64. doi: 10.1186/s13020-018-0222-9. eCollection 2018. Chin Med. 2018. PMID: 30598693 Free PMC article.
-
Exploring dietary changes and supplement use among cancer patients in Norway: prevalence, motivations, disclosure, information, and perceived risks and benefits: a cross sectional study.BMC Nutr. 2024 Apr 26;10(1):65. doi: 10.1186/s40795-024-00872-8. BMC Nutr. 2024. PMID: 38671478 Free PMC article.
-
Efficacy and safety of Lignosus rhinocerus (Cooke) Ryvarden TM02® supplementation for immune-challenged patients with localised breast cancer in remission: a randomised controlled trial.BMC Complement Med Ther. 2025 May 31;25(1):194. doi: 10.1186/s12906-025-04919-6. BMC Complement Med Ther. 2025. PMID: 40450240 Free PMC article. Clinical Trial.
References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
-
- Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, 2002 Jul 15–17. J Natl Cancer Inst. 2003;95:1110–1117. - PubMed
-
- Eustachi A. Complementary therapies in breast cancer patients. Breast Care. 2007;2:209–216.
-
- Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340:1733–1739. - PubMed
-
- Henderson JW, Donatelle RJ. Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med. 2004;10:52–57. - PubMed
LinkOut - more resources
Full Text Sources